Price History

Hover for the daily close. The dotted line marks the period open.

Compare AURA with… →

AURA Key Statistics

As of Sep 4, 2026

Trading

Open: $7.30
Previous Close: $7.37
Day's Range: 7.30–7.57
52-Week Range: 4.73–9.54
Volume: 456.40K
Beta: 0.40

Valuation

Market Cap: $784.01M
P/E Ratio: unprofitable
EPS (ttm): −1.77

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$106.19M
Profit margin: 0.00%
Shares Outstanding: 103.70M
1-Year Return: +17.76%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 671.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AURA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+14.73%−38.16%−15.62%−7.22%−33.70%+38.72%

2021*20222023202420252026*

Year	Return
2026 (partial year)	+38.72%
2025	−33.70%
2024	−7.22%
2023	−15.62%
2022	−38.16%
2021 (partial year)	+14.73%

As of September 4, 2026.

AURA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$106.19M	—
2024	$0.00	−$86.92M	—
2023	$0.00	−$76.41M	—
2022	$0.00	−$58.76M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$112.79M	−$106.19M	—
2024	$0.00	—	−$96.12M	−$86.92M	—
2023	$0.00	—	−$84.99M	−$76.41M	—
2022	$0.00	—	−$60.30M	−$58.76M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AURA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AURA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aura Biosciences, Inc. (AURA) is capitalised at $784.01M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 113 employees.

The 52-week range on file runs from $4.73 to $9.54. AURA last closed at $7.56 on September 4, 2026. That is +$0.19 (+2.58%) against the previous close. The latest close sits 59.83% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $106.19M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.77.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.4. Annualized volatility over the trailing 4 years is 61.67%. Over the trailing twelve months the price has returned +17.76%. Across 3 years the annualized return works out at −10.20%.

Growth & Income

No dividend is on file for AURA.

So far in 2026 the price is +38.72%. The strongest complete calendar year on file is 2024 at −7.22%; the weakest is 2022 at −38.16%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Aura Biosciences, Inc. (AURA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Aura Biosciences, Inc.	AURA	$784.01M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Aura Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Aura Biosciences, Inc.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Visit website →

Aura Biosciences, Inc. (AURA) Stock Analysis